CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Redwood Pharma AB is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Redwood Pharma AB
Ringvagen 100 E 9Th Floor
STOCKHOLM, 11860  Sweden
Filed for Bankruptcy on 7/28/2024
On 7/28/2024, The Board of Directors of Redwood Pharma Aktiebolag announced the filing of a Bankruptcy Application with the Stockholm District Court. The reason for the Bankruptcy Filing is that, despite intensive work in 2024, Redwood Pharma has not found a sound and workable solution for its strained financial situation in the short and medium terms.
This company is no longer actively traded on any major stock exchange.
Business Summary
Redwood Pharma AB is a Sweden-based company, which is primarily focused on pharmaceutical industry. The Company develops IntelliGel, a patented hydrogel drug delivery platform technology. IntelliGel is a patented supramolecular smart drug delivery system with an ability to dissolve water-insoluble and sparingly soluble drugs, or disperse, suspend and stabilize otherwise insoluble drugs. It is an odor-free, clear and transparent hydrogel with low solid content, and forms an invisible patch when applied to a surface. The Company’s development product is focused on treatment of chronic Dry Eye Disease (DED) in post-menopausal women. It is based on a naturally occurring, endogenous molecule found in the body.
(Source: 10-K405)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/202412/31/2023Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

General Information
Number of Employees: 1 (As of 12/31/2023)
Outstanding Shares: 21,231,000 (As of 4/25/2024)
Stock Exchange: STO


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, January 29, 2025